Nail Changes in Patients Receiving Systemic Isotretinoin Therapy

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 27

PMID 39462059

Authors

Dilek Yigit

Nermin Karaosmanoglu

Affiliations

Soon will be listed here.

Abstract

In this study, it was aimed to describe isotretinoin-induced nail changes and increase patients' treatment compliance. A total of 200 patients diagnosed with acne vulgaris were included in the study. 100 of the patients were started systemic isotretinoin treatment and 100 control patients were receiving topical acne treatment. Age and gender of all of the participants, duration of treatment, total doses per month, and type of nail changes were recorded. Patients with persistent nail changes were followed at the 3rd and 6th months after treatment. A total of 34 patients had nail changes in the isotretinoin group. These changes included onychoschizia (55.9%), leukonychia (11.8%), onychorexis (8.8%), median nail dystrophy (5.9%), pyogenic granulomas (5.9%), chronic paronychia and granulation tissue (5.9%), onycholysis (2.9%) and Beau's line (2.9%). The rate of nail changes in the isotretinoin group was significantly higher than in the topical treatment group (34% vs. 11%, p:0.001). Isotretinoin increases the risk of nail changes, primarily onychoschizia. The risk of developing nail changes is not associated with treatment duration but is associated with the total cumulative dose. Nail findings induced by isotretinoin are completely reversible.

References

Brito M, SantAnna I, Galindo J, Rosendo L, Santos J . Evaluation of clinical adverse effects and laboratory alterations in patients with acne vulgaris treated with oral isotretinoin. An Bras Dermatol. 2010; 85(3):331-7. DOI: 10.1590/s0365-05962010000300006. View

Gregoriou S, Banaka F, Rigopoulos D . Isotretinoin-induced transverse leuconychia. J Eur Acad Dermatol Venereol. 2014; 30(2):385-6. DOI: 10.1111/jdv.12819. View

Brzezinski P, Borowska K, Chiriac A, Smigielski J . Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017; 30(4). DOI: 10.1111/dth.12483. View

Goulden V, Layton A, Cunliffe W . Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol. 1994; 131(3):360-3. DOI: 10.1111/j.1365-2133.1994.tb08524.x. View

Alli N, Dogan S . Short-term isotretinoin-induced elkonyxis and median nail dystrophy. Cutan Ocul Toxicol. 2015; 35(1):85-6. DOI: 10.3109/15569527.2014.902380. View

Demirseren D, Kilinc F, Emre S, Akyol M, Metin A, Aktas A . The weeks and the cumulative doses of the first adverse events related to oral isotretinoin in acne patients: analysis of 300 patients. J Dermatolog Treat. 2016; 28(4):309-313. DOI: 10.1080/09546634.2016.1230175. View

Onder M, Oztas M, Oztas P . Isotretinoin-induced nail fragility and onycholysis. J Dermatolog Treat. 2002; 12(2):115-6. DOI: 10.1080/095466301317085426. View

Yung A, Johnson P, Goodfield M . Isotretinoin-induced elkonyxis. Br J Dermatol. 2005; 153(3):671-2. DOI: 10.1111/j.1365-2133.2005.06782.x. View

Legiawati L, Fahira A, Taufiqqurrachman I, Arifin G, Widitha U . Low-Dose versus Conventional-dose Oral Isotretinoin Regimens: A Systematic Review on Randomized Controlled Comparative Studies of Different Regimens. Curr Drug Saf. 2022; 18(3):297-306. DOI: 10.2174/1574886317666220613162225. View

10.

Baran R . [Therapeutic assessment and side-effects of the aromatic retinoid on the nail apparatus]. Ann Dermatol Venereol. 1982; 109(4):367-71. View

11.

Ellis C, Krach K . Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001; 45(5):S150-7. DOI: 10.1067/mjd.2001.113717. View

12.

Chen H, Zhang T, Yin X, Man J, Yang X, Lu M . Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Br J Dermatol. 2021; 186(4):673-683. DOI: 10.1111/bjd.20882. View

13.

Vallerand I, Lewinson R, Farris M, Sibley C, Ramien M, Bulloch A . Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2017; 178(1):76-85. DOI: 10.1111/bjd.15668. View

14.

Rademaker M . Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2011; 51(4):248-53. DOI: 10.1111/j.1440-0960.2010.00657.x. View

15.

Zaenglein A, Pathy A, Schlosser B, Alikhan A, Baldwin H, Berson D . Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74(5):945-73.e33. DOI: 10.1016/j.jaad.2015.12.037. View

16.

Blasiak R, Stamey C, Burkhart C, Lugo-Somolinos A, Morrell D . High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013; 149(12):1392-8. DOI: 10.1001/jamadermatol.2013.6746. View

17.

Bottomley W, Cunliffe W . Median nail dystrophy associated with isotretinoin therapy. Br J Dermatol. 1992; 127(4):447-8. DOI: 10.1111/j.1365-2133.1992.tb00472.x. View

18.

Ozcelik S, Kilic F . Effects of ısotretinoin on the growth rate and thickness of the nail plate. Int J Dermatol. 2021; 60(10):1258-1262. DOI: 10.1111/ijd.15635. View

19.

Benedetto C, Crasto D, Ettefagh L, Nami N . Development of Periungual Pyogenic Granuloma with Associated Paronychia Following Isotretinoin Therapy: A Case Report and a Review of the Literature. J Clin Aesthet Dermatol. 2019; 12(4):32-36. PMC: 6508482. View

20.

Armstrong K, Weinstein M . Pyogenic granulomas during isotretinoin therapy. J Dermatol Case Rep. 2011; 5(1):5-7. PMC: 3163353. DOI: 10.3315/jdcr.2011.1062. View